Latest News

The legislation is effective on January 1, 2026.

Data show the overall use of sodium-glucose cotransporter 2 (SGLT2) inhibitors among study participants with chronic kidney disease (CKD) was about 14.8%.

Pharmacists support acute pain management in patients on MOUD through education, optimizing therapy, guiding analgesia, and ensuring safe transitions of care.

New studies reveal a modest, temporary increase in breast cancer risk linked to hormonal contraceptives, emphasizing the need for informed patient counseling.

Legislation aims to enhance health care access by allowing Medicare reimbursement for pharmacist services in rural areas, improving patient care and convenience.

Tools Like Robotic Dispensing Services, Pharmacogenomics, and Regulatory Changes Are Changing How Pharmacy Works

With Growing Patient Interest in Natural Remedies, Pharmacists Must Understand the Science, Safety, and Limitations of Essential Oils

New research reveals significant non-respiratory complications in hospitalized children with influenza, highlighting the need for improved clinical awareness and antiviral treatment.

FDA approves an 8-mg aflibercept injection for macular edema following retinal vein occlusion (RVO), offering flexible dosing options for improved patient care.

Advanced IHC assays enhance HER2-low breast cancer detection, improving treatment eligibility for trastuzumab deruxtecan.

Particularly, younger women with chronic kidney disease (CKD) experienced the greatest survival disadvantage.

Counsel patients about effective remedies for pediatric colds, sore throats, and safe OTC options for adults with hypertension to alleviate symptoms.

Proactive Monitoring and Patient Education Are Key Roles for Pharmacists

Pharmacists Can Educate Patients About Symptoms of Menopause, Associated Chronic Conditions, and Management Options

CDC's recent statement raises concerns about vaccine safety and autism links, igniting debate among health experts and fueling vaccine hesitancy.

Dexcom Smart Basal optimizes basal insulin dosing for type 2 diabetes, enhancing management with personalized recommendations and a 15-day CGM sensor.

The findings from the BATURA clinical trial were presented at the 2025 ACAAI Annual Scientific Meeting.

A recent study reveals diverse long COVID trajectories, highlighting the need for further research to understand symptoms and recovery variability.

The biosimilars can be used to treat osteoporosis and cancer-related bone loss in certain populations.

The program’s legitimacy rests on transparency, audits, and ensuring benefits reach vulnerable patients.